摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-溴-6,7-二氢苯并[b]噻吩-4(5h)-酮 | 2513-49-7

中文名称
5-溴-6,7-二氢苯并[b]噻吩-4(5h)-酮
中文别名
5-溴-6,7-二氢苯并[B]噻吩-4(5H)-酮
英文名称
4,5,6,7-tetrahydro-4-oxo-5-bromo-benzothiophene
英文别名
5-bromo-4,5,6,7-tetrahydrobenzothiophen-4-one;5-bromo-6,7-dihydrobenzothiophen-4-one;5-Brom-4-keto-4,5,6,7-tetrahydro-thionaphthen;5-bromo-6,7-dihydro-5H-benzo[b]thiophen-4-one;5-bromo-6,7-dihydro-1-benzothiophen-4(5H)-one;5-bromo-6,7-dihydrobenzo[b]thiophen-4(5H)-one;5-bromo-6,7-dihydro-5H-1-benzothiophen-4-one
5-溴-6,7-二氢苯并[b]噻吩-4(5h)-酮化学式
CAS
2513-49-7
化学式
C8H7BrOS
mdl
——
分子量
231.113
InChiKey
KBLQDFSWVMPYEM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    79-81 °C
  • 沸点:
    316.2±42.0 °C(Predicted)
  • 密度:
    1.691±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    45.3
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2934999090

SDS

SDS:fe24a4c832d4bd3401554ef3cebbd0d8
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-溴-6,7-二氢苯并[b]噻吩-4(5h)-酮copper(I) oxidesodium hydroxide硫酸铁粉 、 sodium hydride 、 溶剂黄146potassium nitrate 作用下, 以 乙醇乙腈 为溶剂, 反应 68.5h, 生成 4,5,6,7-tetrahydro-2-acetylamino-4-oxo-benzothiophene-5-acetic acid
    参考文献:
    名称:
    Synthesis and pharmacological evaluation of 4,4a,5,6-tetrahydro-2H-thieno[2,3-h]cinnolin-3-ones bioisosters of antihypertensive and antithrombotic benzo[h]cinnolinones
    摘要:
    The 8-acetylamino-4,4a,5,6-tetrahydro-2H-thieno[2,3-h]cinnolin-3-one (2b) has been synthesized and tested for its pharmacological profile in comparison with the bioisoster 8-acetylamino-4,4a,5,6-tetrahydrobenzo(h)cinnolin-3(2H)one (1b), which we reported to be a potent antihypertensive and antithrombotic agent. The new compound retained antithrombotic properties which were higher than those of acetylsalicylic acid but without significant antihypertensive activity. Conformational analysis performed by molecular mechanic calculations suggests that the lack of activity could be due to a different orientation of the acetylamino group in the 2 compounds. In addition, the unsubstituted term 2a was found to be comparable to ASA as an antithrombotic agent.
    DOI:
    10.1016/0223-5234(91)90004-7
  • 作为产物:
    描述:
    4,5,6,7-四氢-4-苯并噻吩copper(ll) bromide 作用下, 以 乙酸乙酯 为溶剂, 以83%的产率得到5-溴-6,7-二氢苯并[b]噻吩-4(5h)-酮
    参考文献:
    名称:
    通过金属或适当的氯代酮的酶还原和氨基环氧化锌选择性缩合反应合成长效HIV蛋白酶抑制剂
    摘要:
    本文介绍了一种合成HIV蛋白酶抑制剂的新收敛方法,该方法被设计用于长效制剂。合成中的独特特征包括不对称氢化以及关键氯代酮中间体的酶促还原,以设定相应环氧化物中的苏式立体化学,以及后者与合适的功能化酰胺衍生物的烯醇锌的非对映选择性偶联。
    DOI:
    10.1002/adsc.201300074
点击查看最新优质反应信息

文献信息

  • [EN] 3-ARYLOXY/ THIO-2, 3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE<br/>[FR] 3-ARYLOXY/THIO-2, 3-SUBSTITUE PROPANAMINES ET LEUR UTILISATION POUR INHIBER LE RECAPTAGE DE LA SEROTONINE ET DE LA NOREPINEPHRINE
    申请人:LILLY CO ELI
    公开号:WO2004043903A1
    公开(公告)日:2004-05-27
    There is provided a compound of formula (I) wherein A is selected from -O- and -S-; X is selected from phenyl optionally substituted with up to 5 substituents each independently selected from halo, C1-C4 alkyl and C1-C4 alkoxy, thienyl optionally substituted with up to 3 substituents each independently selected from halo and C1-C4 alkyl, and C2-C8 alkyl, C2-C8 alkenyl, C3-C8 cycloalkyl and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, -CF3, -CN and -CONH2; Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, up to 5 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, nitro, acetyl, -CF3, -SCF3 and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C1-C4 alkyl; Z is selected from OR3 or F, wherein R3 is selected from H, C1-C6 alkyl and phenyl C1-C6 alkyl; R1 and R2 are each independently H or C1-C4 alkyl; and pharmaceutically acceptable salts thereofwith the proviso that when Y is optionally substituted phenyl or optionally substituted 1,3-benzodioxolyl and Z is OR3 and X is optionally substituted phenyl then A is -S-.
    提供一种化合物,其化学式为(I),其中A从-O-和-S-中选择;X从苯基选项地取代,每个取代基可独立地从卤素、C1-C4烷基和C1-C4烷氧基中选择最多5个取代基,噻吩基选项地取代,每个取代基可独立地从卤素和C1-C4烷基中选择最多3个取代基,以及C2-C8烷基、C2-C8烯基、C3-C8环烷基和C4-C8环烷基烷基,每个基可选地取代,每个取代基可独立地从卤素、C1-C4烷基、C1-C4烷氧基、C1-C4烷基-S(O)n-(其中n为0、1或2)、-CF3、-CN和-CONH2中选择;Y从苯基、萘基、二氢苯并噻吩基、苯并噻唑基、苯并异噻唑基、喹啉基、异喹啉基、萘啉基、噻吩吡啉基、茚基、1,3-苯并二氧杂环戊基、苯并噻吩基、吲哚基和苯并呋喃基中选择,每个基可选地取代,最多可独立地从卤素、C1-C4烷基、C1-C4烷氧基、C1-C4烷基-S(O)n-(其中n为0、1或2)、硝基、乙酰基、-CF3、-SCF3和氰基中选择最多4个或在可能的情况下最多5个取代基;当Y为吲哚基时,它可以被取代或进一步被N-取代基取代,N-取代基从C1-C4烷基中选择;Z从OR3或F中选择,其中R3从H、C1-C6烷基和苯基C1-C6烷基中选择;R1和R2各自独立地为H或C1-C4烷基;以及其药学上可接受的盐,但有一个条件,即当Y为可选地取代的苯基或可选地取代的1,3-苯并二氧杂环戊基,Z为OR3且X为可选地取代的苯基时,A为-S-。
  • [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases
    申请人:Dahnke Karl Robert
    公开号:US20080306082A1
    公开(公告)日:2008-12-11
    The present invention provides compounds of Formula I: useful in the treatment of cancer and inflammatory diseases.
    本发明提供了一种公式I的化合物:用于治疗癌症和炎症性疾病。
  • [EN] 3-ARYLOXY/THIO-3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPHINEPHRINE REUPTAKE<br/>[FR] COMPOSES PHARMACEUTIQUES
    申请人:LILLY CO ELI
    公开号:WO2004043904A1
    公开(公告)日:2004-05-27
    There is provided a compound of formula (I) wherein A is selected from -O- and -S-; X is selected from C2-C8 alkyl, C2-C8 alkenyl, C3-C8 cycloalkyl and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, -CF3, -CN and -CONH2; Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, 5 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, nitro, acetyl, -CF3, -SCF3 and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C1-C4 alkyl; Z is selected from H, OR3 or F, wherein R3 is selected from H, C1-C6 alkyl and phenyl C1-C6 alkyl; R1 and R2 are each independently H or C1-C4 alkyl; with the proviso that, when Z is H, then Y may not be optionally substituted phenyl or optionally substituted naphthyl.
    提供一种具有以下结构的化合物(I):其中A从-O-和-S-中选择;X从C2-C8烷基,C2-C8烯基,C3-C8环烷基和C4-C8环烷基烷基中选择,每种基团可能分别被选自卤素,C1-C4烷基,C1-C4烷氧基,C1-C4烷基-S(O)n-(其中n为0,1或2),-CF3,-CN和-CONH2的最多3个取代基所取代;Y从苯基,萘基,二氢苯并噻吩基,苯并噻唑基,苯并异噻唑基,喹啉基,异喹啉基,萘啉基,噻吩吡啉基,茚基,1,3-苯并二氧杂环戊基,苯并噻吩基,吲哚基和苯并呋喃基中选择,每种基团可能分别被选自卤素,C1-C4烷基,C1-C4烷氧基,C1-C4烷基-S(O)n-(其中n为0,1或2),硝基,乙酰基,-CF3,-SCF3和氰基的最多4个或在可能的情况下5个取代基所取代;当Y为吲哚基时,它可以被选自C1-C4烷基的N-取代基取代或进一步取代;Z从H,OR3或F中选择,其中R3从H,C1-C6烷基和苯基C1-C6烷基中选择;R1和R2分别独立地为H或C1-C4烷基;但是,当Z为H时,Y可能不是可选择地取代的苯基或可选择地取代的萘基。
  • Novel spla2 inhibitors
    申请人:——
    公开号:US20030236232A1
    公开(公告)日:2003-12-25
    A class of novel benzo(b)thiophene is disclosed together with the use of such compounds for inhibiting sPLA 2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    一种新型苯并(b)噻吩类化合物被揭示,以及利用这类化合物抑制sPLA2介导的脂肪酸释放,用于治疗炎症性疾病,如感染性休克。
  • N-Imidazolyl-4-chromanones, N-imidazolyl-1-tetralones, and their alcohols as hypolipemic agents raising high-density lipoproteins
    作者:Paolo Cozzi、Umberto Branzoli、Pier Paolo Lovisolo、Gaetano Orsini、Germano Carganico、Antonio Pillan、Augusto Chiari
    DOI:10.1021/jm00153a016
    日期:1986.3
    3-(1-imidazolyl)chroman-4-ones and 2-(1-imidazolyl)-1-tetralones II, some of their alcohols, and some related compounds were synthesized and tested for hypolipidemic activity. Compounds II, bearing appropriate lipophilic substituents on the phenyl ring, strongly reduced total serum cholesterol while raising high-density lipoprotein cholesterol in diet-induced hypercholesterolemic rats. 3-(1-Imidazolyl)chroman-4-ols
    合成了一系列3-(1-咪唑基)苯并二氢吡喃-4-酮和2-(1-咪唑基)-1-四氢萘酮II,它们的一些醇和一些相关化合物,并测试了其降血脂活性。在饮食诱导的高胆固醇血症大鼠中,在苯环上带有适当亲脂性取代基的化合物II大大降低了血清总胆固醇,同时提高了高密度脂蛋白胆固醇。对应于II的3-(1-咪唑基)苯并吡喃-4-醇和2-(1-咪唑基)-1-四醇保留了降血脂活性,同时除去了与咪唑相邻的羰基或羟基,得到了惰性化合物。尽管许多活性化合物显着增加了肝脏的重量,但作为模型研究的一种化合物是6-氯-3-(1-咪唑基)-2,3-二氢-4H-1-苯并吡喃-4-酮(5)引起的。没有过氧化物酶体增殖。化合物5和相应的醇40,作为酮和醇系列的代表,在降血脂正常大鼠中显示出显着的降血脂活性。在胆固醇生物合成中检测到的某些化合物抑制乙酸盐的掺入,但没有抑制HMG-CoA还原酶。选择5-溴-6-羟基-2-(1-咪唑基)-3
查看更多